3D Tissue Models

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2010 Migration or evasion Nat Med. 2010 Jan;16(1):35-6
2. 2010 Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus Cancer J. 2011 Sep;17(5):300-1
3. 2010 T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res. 2011 Sep 1;17(17):5736-47. Epub
4. 2010 Summit on cell therapy for cancer: the importance of the interaction of multiple disciplines to advance clinical therapy. J Transl Med. 2011 Jul 8;9:107
5. 2010 Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity Pigment Cell Melanoma Res. 2011 Aug;24(4):673-9. doi: 10.1111/j.1755-148X.2011.00878.x.
6. 2010 Human papillomavirus status in young patients with head and neck squamous cell carcinoma Int J Cancer. 2011 May 23. doi: 10.1002/ijc.26195
7. 2010 Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies J Biomed Biotechnol. 2011;2011;702146. Epub
8. 2010 Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes PLoS One. 2011 Mar 14;6(3):e17848.
9. 2010 Evaluation of the high-pressure extrusion technique as a method for sizing plasmid DNA-containing cationic liposomes J Liposome Res.
10. 2010 Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody Clin Cancer Res. 2011 Apr 15;17(8):2270-80. Epub
11. 2010 Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors PLoS One. 2011 Feb 15;6(2):e16819
12. 2010 Skin-Depigmenting Agent Monobenzone Induces Potent T-Cell Autoimmunity toward Pigmented Cells by Tyrosinase Haptenation and Melanosome Autophagy J Invest Dermatol. 2011 Jun;131(6):1240-51. Epub
13. 2010 Cancer immunology Curr Opin Immunol. 2011 Apr;23(2):234-6. Epub
14. 2010 Therapeutic vaccination against human papilloma virus induced malignancies Curr Opin Immunol. 2011 Jan 13, 23:252-257
15. 2010 Immunotherapy for persistent viral infections and associated disease Trends Immunol. 2011 Jan 10, 32:97-103
16. 2010 Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol. 2011 Jan;1 2(1):45-53. Epub
17. 2010 DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in Dendritic cells Immunome Res. 2010 Nov 19;6:10
18. 2010 Minimal information about T cell assays: the process of reaching the community of T cell immunologistis in cancer and beyond Cancer Immunol Immunother. 2011 Jan;60 (1):15-22
19. 2010 Enhancement of proliferation and downregulation of TRAIL expression on CD8+ T cells by IL-21. Eur J Immunol. 2010 Nov;40(11):2990-2
20. 2010 Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm Cancer Res. 2010 Nov 1;70(21):8339 – 46. Epub
21. 2010 Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses J Infect Dis. 2010 Oct 15;202(8):1200 – 11
22. 2010 Separate roles for antigen recognition and lymph node inflammation in CD8+ memory T cell formation. ;185(6):3167 -73
23. 2010 Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T cell responses Proc Natl Acad Sci USA 2010 Jun 29;107 (26) : 11895-99
24. 2010 Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PloS One. 2010 May 13;5(5):e10626
25. 2010 The detection of circulating Human Papillomavirus (HPV)-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int. J. Cancer
26. 2010 Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol. 2010 May 14; 40 (7): 1973-84
27. 2010 Antigen-Specific active immunotherapy for ovarian cancer Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007287
28. 2009 Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res. ;15(3):1086-95
29. 2009 Vaccination against Human Papillomavirus 16 for Vulvar Intraepithelial Neoplasia N Engl J Med. 2009 Nov 5;361(19):1838-47
30. 2009 “MIATA”-minimal information about T cell assays Immunity 2009 Oct 16;31(4);31(4):527-8.
31. 2009 Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma Clin Cancer Res. 2009 Oct 15;15(20):6341-7. Epub
32. 2009 MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways Traffic. 2009 Oct;10(10):1528-42. Epub
33. 2009 Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer. 2009 Nov 1;125(9):2104-13
34. 2009 Effective CD8(+) T cell priming and tumor protection by enterotoxin B subunit-conjugated petides targeted to dentritic cells. Vaccine. 2009 Aug 20;27(38):5252-8. Epub 2009 Jul 2
35. 2009 DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+) CD4(+) Treg. Eur J Immunol. 39(7):1765-1773
36. 2009 Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity Proceedings of the National Academy of Science U S A. 106(16):6730-5
37. 2009 2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation. Bioorg Med Chem Lett. 19(8):2249-51
38. 2009 Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition J Pathol. 218(2):222-31
39. 2009 Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients J Invest Dermatol
40. 2009 Chirality of TLR-2 ligand Pam(3)CysSK(4) in fully synthetic peptide conjugates critically influences the induction of specific CD8(+) T-cells Mol Immunol. 46(6):1084-91
41. 2008 Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine Clin Cancer Res 14(1): 178-87
42. 2008 NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Molecular Immunology, 45(15):3917-25
43. 2008 Cancer immunotherapy by dendritic cells Immunity. 29(3):372-83
44. 2008 Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int J Cancer 123(4): 838-45
45. 2008 Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healty subjects and patients with cervical neoplasia. Int. J Cancer 123 (1) : 146-52
46. 2008 Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines Nat Rev Cancer 8(5): 351-60
47. 2008 Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation Eur J Immunol 38(4): 1033-42
48. 2008 Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen Cancer Res 68(3): 893-900
49. 2008 Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and –DP as a restriction element. Int J Cancer 122(3): 486-94
50. 2008 Dendritic cells in cancer immunotherapy Adv Cancer Res 99: 363-407
51. 2008 Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high risk HPV16 in end stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14(1): 169-77,
52. 2007 Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 9;25(8):1379-1389
53. 2007 Distinct uptake mechanisms but similar5 intracellular processing of two different toll-like receptor ligand peptide conjugates in dendritic cells. J Biol Chem 282(29): 21145-21159
54. 2007 Identification of T cell epitopes for cancer immunotherapy Leukemia 21(9): 1859-1874
55. 2007 Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 104(29): 12087-12092
56. 2007 Design and development of synthetic peptide vaccines: past, present and future Expert Rev Vaccines 6: 591-603
57. 2007 CD8+ CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivitity. J Immunol 179(8): 5033-5040
58. 2007 Characterization of antigen-specific immune responses induced by canarypox virus vaccines J Immunol 179(9): 6115-6122
59. 2007 Human papillomavirus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and –D as a restriction element Int J Cancer
60. 2007 Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. Exp. Med 204(4): 879-891
61. 2007 P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy. Int. J. Cancer
62. 2007 High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer Cancer Res. 1;67(1):354-361
63. 2007 Expression of cullular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin. Cancer Res. 1;13(1):206-214
64. 2006 Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy Clin. Cancer Res. 12: 3130-3136
65. 2006 Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination. Immunity 25(6):885-894
66. 2006 Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy J. Adv Drug Deliv Rev. 1;58(8):916-930,
67. 2006 Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus Eur J. Immunol. 36(9):2410-2423
68. 2006 BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes Leukemia: 20(10): 1738-1750
69. 2006 Macrophages are vital in spontaneous intraocular tumor eradication Invest. Ophthalmol. Vis. Sci. 47: 2959-2965
70. 2006 Vaccination for treatment and prevention of cancer in animal models J. Adv. Immunol. 90: 175-213
71. 2006 CD8 T-cell recognition of human 5T4 oncofetal antigen Int. J. Cancer
72. 2006 Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol. 176: 4573-4580
73. 2006 Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: towards synthetic epitope-based vaccines Bioorg. Med. Chem. Lett. 16: 3258-3261
74. 2006 Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants Nat. Med. 12: 417-424
75. 2006 Ins and outs of dendritic cells J. Int. Arch. Allergy Immunol. 140: 53-72
76. 2006 Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int. J. Cancer 118: 950-956
77. 2006 Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cercical infection and neoplasia. Int. J. Cancer 118, 675-683
78. 2005 SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. Blood 105: 1153-1161
79. 2005 C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L Nat. Chem. Biol. 1: 377-382
80. 2005 Maintenanceof immune tolerance depends on normal tissue homeostasis J. Immunol. 175: 4247-4254
81. 2005 CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts. Cancer Res. 65: 6984-6989
82. 2005 Cancer immunology: cat and mouse games. Nature 437:41-42
83. 2005 Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model Vaccine 23: 5271-5280
84. 2005 Detection of human papillomavirus (HPV) 16-specific CD4_ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment Clin. Cancer Res. 11: 5273-5280
85. 2005 Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res. 65: 6443-6449
86. 2005 Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function. J. Immunol. 175: 855-863
87. 2005 Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J. Immunol. 174: 7815-7822
88. 2005 Escort service for cross-priming. Nat. Immunol. 6: 543-544
89. 2005 Safety in numbers Eur. J. Hum. Genet.: 13: 795-798
90. 2005 Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer Int. J. Cancer 114: 274-282
91. 2005 Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization Clin.Cancer Res. 11: 2576-2582
92. 2004 Dendritic cell immunotherapy: mapping the way, Nature Med. 10: 475-480
93. 2004 Revival of the regulatory T cell: new targets for drug development. Drug Discov. Today 9: 310-316
94. 2004 Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells Cancer Immunol. Immunother. 53: 978-986
95. 2004 The tumoricidal activity of memory CD8(+) T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment J. Immunol. 172: 6074-6079
96. 2004 Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 64: 5449-5455
97. 2004 Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model Vaccine: 23: 305-311
98. 2004 Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer J. Cancer: 114: 274-282
99. 2004 Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th!-type responses while selectively activating IL-1—producing CD4+ T cells. Hum. Immunol. 65: 1344-1355
100. 2004 Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication J. Immunol. 173: 6753-6759
101. 2004 Intraocular tumor antigen drains specifically to submandibular lymph nodes resulting in an abortive cytotoxic T cell reaction. J. Immunol. 172: 1567-1574
102. 2003 Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients Cancer Gene Ther. 10: 509-517
103. 2003 Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33: 2645-2654
104. 2003 Cellular immunotherapy – towards direct DC activation for licence to kill In: Smith Sibinga, C.Th. & Leij, L.F.M.H. de (Ed.), Cellular Engineering and Cellular Therapies, pp. 89-94, Kluwer Academic Publishers
105. 2003 Interplay between human papillomaviruses and dendritic cells Curr. Topics Microb. Immunol. 276: 215-240
106. 2003 Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells Transplantation 76: 1608-1615
107. 2003 Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther. 10: 2020-2028
108. 2003 Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33: 2645-2654
109. 2003 Magnitude and polarization of p53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors Int. J. Cancer 107: 425-433
110. 2003 Interplay between human papillomaviruses and dendritic cells Curr. Top. Microbiol. Immunol. 276: 215-240
111. 2003 CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis Arthritis Rheum. 48: 1452-1460
112. 2003 Differential maturation of megakaryocyte progenitor cells from cord blood and mobilized peripheral blood. Exp. Hematol. 31: 324-330
113. 2003 Frequent display of human papillomavirus type 16 E6-specific memory THelper cells in the healthy population as witness of previous viral encounter Cancer Res. 63: 636-641
114. 2003 Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum. Immunol. 64: 245-255
115. 2002 Effective immunotherapy of cancer in MUC1-transgenic mice using cloned cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope J. Immunother. 25: 46-56
116. 2002 The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res. 89: 275-284
117. 2002 Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells Cancer Res. 62: 6187-93
118. 2002 Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes Immunol. Reviews 188: 177-182
119. 2002 Differential kinetics of antigen-specific CD4(+) and CD8(+) T cell responses in the regression of retrovirus-induced sarcomas. J. Immunol. 169: 3191-3199
120. 2002 In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J. Immunol. 168: 3755-3762
121. 2002 Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine Clin. Cancer Res. 8: 1019-1027
122. 2002 Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides J. Immunol. 169: 350-358
123. 2002 CD40 stimulation leads to effective therapy of CD40-negative tumors through induction of strong systemic cytotoxic T-lymphocyte immunity Proc.Natl.Acad.Sci. USA, 99: 5561-5566
124. 2002 Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects Cancer Res. 62: 472-479
125. 2002 Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8(+) CTL responses in vivo J. Immunol. 168: 2240-2246
126. 2002 Immunotherapy of cancer through targeting of the p53 tumor antigen. Arch. Immunol. Ther. Exp. 50: 297-305
127. 2001 Strategies for improved antigen delivery into dendritic cells Trends Mol Med. 7: 91-4
128. 2001 A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway J Gen Virol. 82: 2131-42
129. 2001 Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol. 166: 3678-87
130. 2001 Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res. 7: 788s-795s
131. 2001 Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A. 98: 11515-20
132. 2001 Rejection of Intraocular Tumors by CD4(+) T Cells Without Induction of Phthisis. J Immunol. 167: 5832-5837
133. 2001 Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice Int J Cancer. 91: 385-92.
134. 2001 Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells, J Exp Med. 194: 657-67.
135. 2001 Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance J of Immunol 167: 2522-2528
136. 2001 Involvement of inhibitory NKRs in the survival of a subset of memory phenotype CD8+ T cells. Nature Immunol 2; 430-435
137. 2001 Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T cell epitopes that induce protective anti-tumor immunity in HLA-A2/Kb transgenic mice Int J Cancer 91: 385-392
138. 2001 Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K9b)-trangenic mice. Int.J. Cancer 91: 385-392,
139. 2001 Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur. J. Immunol. 31:146-155
140. 2001 T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serious epithelial ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 94: 114-120
141. 2001 Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J.Exp.Med. 193: 73-88
142. 2001 Results of a Phase I/II vaccination study in colorectal cancer patients using a canarypox virus encoding the human wild-type p53 gene. Cancer Gene Therapy 8: O80 Suppl
143. 2001 T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 94: 114-20
144. 2001 Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2: 962-70.
145. 2001 Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. J Cell Biol. 155: 53-63.
146. 2001 Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 194: 823-32.
147. 2001 Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 194: 481-9.,
148. 2001 Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer Eur J Immunol. 31: 146-55
149. 2001 Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine. 19: 3652-60.,
150. 2001 Antigen loading of MHC class I molecules in the endocytic tract. Traffic. 2: 124-37.,
151. 2001 Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer. 91: 612-8
152. 2001 Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells J Immunol. 166: 5236-44.
153. 2000 Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. J. Immunol. 165: 7308-15
154. 2000 The role of CD40 in peripheral T cell tolerance and immunity. J.Mol.Med. 78:363-71
155. 2000 High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes Cancer Res. 60: 5508-13
156. 2000 Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site J. Immunol. 164: 1898-1905
157. 2000 Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma J. Immunother. 23: 255-266
158. 2000 MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells J. Immunol. 164: 4500-4506
159. 2000 Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 95: 3162-3167
160. 2000 BCR-ABL directed immunotherapy: a virtual reality? Leuk. Lymphoma 38: 175-181
161. 2000 Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL Int.J.Cancer 87: 253-260
162. 2000 Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin J. Immunol. 165: 869-877
163. 2000 Strategies for immunotherapy of cancer Adv. Immunol. 75: 235-282
164. 2000 Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or –dependent stimuli. J.Exp.Med. 192: 145-150
165. 2000 P53: a potential target antigen for immunotherapy of cancer Ann. NY Acad. Sci. 910: 223-233
166. 2000 Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J.Exp.Med. 192: 483-494
167. 2000 Importance of CD4(+) T helper cell responses in tumor immunity Immunol. Letters 74: 75-79
168. 2000 Design and evaluation of antigen-specific vaccination strategies against cancer Curr. Opin. Immunol. 12: 576-582
169. 2000 Superior tumor protection induced by a cellular vaccine carrying a tumor specific T helper epitope by genetic exchange of CLIP. Cancer Research, 60: 6427-33
170. 1999 Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. European J. of Cancer, vol. 35, no. 6: 946-952
171. 1999 Cytotoxic T lymphocyte priming versus cytotoxic T lymphocyte tolerance induction: a delicate balancing act involving dendritic cells. Haematologica 84: 26-27
172. 1999 Immunotherapeutic strategies for cervical squamous carcinoma. Hematol.Oncol.Clin.North Am. 13: 259-273
173. 1999 Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur.J.Cancer, 35: 946-952
174. 1999 Peptide vaccination. Gene Therapy, Ed. T. Blankenstein, Birkhauser Verlag, Berlin, 349-355
175. 1999 Anti-tumor immunotherapy with synthetic peptides representing tumor-associated T cell epitopes: imlications for peptide-based vaccination of cervical cancer Medical Intelligence Unit
176. 1999 Priming or tolerization of tumor-specific T cell immunity; lessons from murine tumor models Gann monograph on Cancer Research, 48: 73-81
177. 1999 Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein J. Exp. Med. , 190: 1033-1038
178. 1999 Adenoviruses activate human dendritic cells without polarization toward a T helper type 1-including subset. J. of Virology, 73: 10245-10253
179. 1999 Succesful immunotherapy of an intraocular tumor in mice. Cancer Research 59: 5250-5254
180. 1999 Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition J. of experimental medicine, 190, no.2: 169-176
181. 1999 Specific immunotherapy of chronic autoimmune disease. How to translate the experience of the experimental models into novel treatment modalities. Proceedings of the Colloquium, Amsterdam 12-14 maart 1998 (ISBN 90-6984-259-9) 73-88
182. 1999 A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an lib2a2 construct. Blood, 94: 1038-1045
183. 1999 Polyriboinosinic polyribocytidylic acid (Poly (I:C) induces stable maturation of functionally active human dendritic cells. J. of Immunology, 163: 57-61
184. 1999 T-cell mediated immunotherapy of cancer. Textbook of malignant hematology, 447-461
185. 1999 HLA and susceptibility to cervical neoplasia Human Immunology, 60: 337-342
186. 1999 Immunotherapeutic strategies for cervical squamous carcinoma. Hematology – Oncology Clinics of North America, 13: 259-273
187. 1999 CD4 T cells and their role in antitumor immune responses J. of Experimental Medicine, 5: 753-756
188. 1999 Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. Eur. J. of Obstetrics & Gynecology and Reproductive Biology 83 (1999) 201-206
189. 1999 A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with and Iib2a2 construct. Blood, vol. 94, no. 3: 1-9
190. 1999 Identification of a conserved universal Th Epitope in HIV-1 reverse transcritpase that is processed and presented to HIV specific CD4+ T cells by at least four unrelated HLA-DR molecules J. of Immunology, 162: 152-160
191. 1999 Polyriboinosinic polyribocytidiylic acid (poly (I:C) induces stable maturation of functionally active human dendritic cells J. of Immunology, 163: 1-5
192. 1999 CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T lymphocyte tolerance and augments anti-tumor vaccine efficacy Nature Medicine, vol. 5, no. 5: 774-778
193. 1998 Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J. of Immunotherapy 21(6); 399-408
194. 1998 Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction J. of Immunology 160: 171-179
195. 1998 T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483
196. 1998 Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. of Immunology 160: 4449-4456
197. 1998 Cutting edge: cross-rpiming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells J. of Immunology 161: 3808-3812
198. 1998 Characterization of HLA-B57 restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J. of General Virology 79: 2191-2201
199. 1998 Specific T helper cell requirement for optimal induction of cytotoxic T lymhocytes against major histocompatibility complex class II negative tumors J. Exp. Med. Vol. 187, no. 5: 693-702
200. 1998 CD80 transfected acute myeloid leukemia cells induce primary allogeneic T cell responses directed at patient specific minor histocompatibility antigens and leukemia associated antigens Blood vol. 92, no. 5: 1677-1684
201. 1998 CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Immunology, vol. 10: 443-448
202. 1998 L1-specific protection from tumor challenge elicited by HPV16 virus-like particles Virology 250: 371-376
203. 1998 Effects of thrombopoietin on the proliferation and differentiation of primitive and mature haemopoietic progenitor cells in cord blood. British J. of Haematology, 101: 425-435
204. 1998 BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a psecial pattern of CrkL phosphorylation. British J. of Haematology, 103: 1109-1115
205. 1998 Immunization with human papillomavris type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-resreicted protection to HPV16-induced tumor cells. Cancer Research 58: 724-731
206. 1998 Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T lymphocyte epitopes Cancer Research 58: 3087-3093
207. 1998 Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC1 Cancer Research 58: 3094-3100
208. 1997 Do epitopes derived from autoantigens display low affinity for MHC class I? Immunology Today 18: 97-98
209. 1997 Targeting of cytotoxic T cells against leukemic B cells by bispecific antibody (aCD3 x aCD19) does not distract the T cell from its primary target J. of Immunology 159: 5545-5549
210. 1997 Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes J. Exp. Med. 1997; 186: 695-704
211. 1997 Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific mage-2 gene product. Int. J. Cancer 73: 125-130
212. 1997 Affinity, specificity and T-cell-receptor diversity of melanoma-specific CTL generated in vitro against a single tyrosinase epitope. Int. J. Cancer 72: 1122-1128
213. 1997 Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis Eur. J. Immunol. 27: 3492-3498
214. 1997 Analogues of CTL epitpes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer 70: 302-309
215. 1997 HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells Blood 90: 1083-1090
216. 1997 Activation or frustration of anti-tumor responses by T-cell-based immune modulation Immunology 9: 323-327
217. 1997 HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS J. of Immunology 159: 3648-3654
218. 1997 Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion Proc. Natl., Acad. Sci USA 94: 14660-14665
219. 1997 Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Human Immunology 53: 81-89
220. 1996 Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. J. of Immunology 156: 3196-3206,
221. 1996 Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer Clinical Cancer Research, Vol. 2, 1825-1828
222. 1996 Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Research 56, 582-588
223. 1996 The rat cim effect: TAP allele-dependent changes in a class I MHC anchor motif and evidence against C-terminal trimming of peptides in the ER Immunity 4, 159-165
224. 1996 Cellular immunity against human papillomavirus associated cervical cancer. Seminars in Virology 7: 117-123
225. 1996 Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. of Immunology 156: 3308-3314
226. 1996 Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors J. of Immunology 156 3911-3918
227. 1996 Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Procl. Natl. Acad. Sci. USA 93: 7855-7860
228. 1996 Peptide-based cancer vaccines. Current Opinion in Immunology 8: 651-657
229. 1996 Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts Int. J. Cancer 66: 1-6
230. 1996 B lymphocytes secrete antigen-presenting vesicles J. Exp. Med. 183: 1161-1172
231. 1996 Protective antitumor immunity induced by immunization with completely allogeneic tumor cells Cancer Research 56: 3782-3787
232. 1996 Detailed motifs for peptide binding to HLA-A*0201. Peptides in Immunology 245-250
233. 1996 Recognition of BCR-ABL positive leukemic blasts by human CD4* T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide Blood 88: 001-006
234. 1996 Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA 93: 14704-14707
235. 1996 Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD 19 antigen-derived synthetic peptide J. of Immunotherapy 19: 346-356
236. 1996 Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnology 2: 241-251
237. 1996 Decreased tumor surveillance in perforing-deficient mice. J. Exp. Med. 184: 1781-1790
238. 1996 Immunological and other active agents Elsevier Science BV. The Scientific Bases of Cancer Chemoprevention pp. 163-171
239. 1996 The current status of therapeutic HPV vaccine. Annals of Medicine 28: 471-477
240. 1996 Peptide specificity of alloreactive CD4 positive T lymphocytes directed against a major histocompatibility complex class I disparity. Transplantation 62: 1485-1491
241. 1996 Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201 binding peptides from the melan-A/MART-1 self antigen Eur. J. Immunol. 26: 1683-1689
242. 1996 A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 5: 115-124
243. 1995 The use of Epstein-Barr Virus-Transformed B Lymphocyte Cell Lines in a Peptide-Reconstitution Assay: Identification of CEA-Related HLA-A*0301-Restricted Potential Cytotoxic T-Lymphocyte Epitopes J. of Immunotherapy, 18: 77-85
244. 1995 Ontwikkeling peptide vaccin voor baarmoederhalskanker Kanker 19, 6-8
245. 1995 An Adenovirus Type 5 Early Region 1B-Encoded CTL Epitope-Mediating Tumor Eradication by CTL Clones is Down-Modulated by an Activated ras Oncogene1 J. of Immunology 154: 3396-3405
246. 1995 MHC Class II compartments and the Kinetics of Antigen Presentation in Activated Mouse Spleen Dendritic Cells. J. of Immunology 154: 5715-5724
247. 1995 Functional and ultrastructural aspects of antigen processing by dendritic cells. Dendritic Cells in Fundamental and Clinical Immunology 2, 227-232
248. 1995 Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 1995, 25: 2638-2642.
249. 1995 Bone Marrow-derived dendritic cells pulsed with syntheti tumour peptides eleicit protective and therapeutic antitumour immunity. Nature Medicine 1, 1297-1302
250. 1995 An HLA Class I Peptide-Binding Assay Based on Competition for Binding to Class I Molecules on Intact Human B cells. Identification of Conserved HIV-1 Polymerase Peptides Binding to HLA-A*0301. Human Immunology 44, 189-198
251. 1995 Both Immunization with Protein and Recombinant Vaccinia Virus Can stimulate CTL Specific for the E7 Protein of Human Papilloma Virus 16 in H-2d Mice. Scand. J. Immunol. 42, 557-563
252. 1995 Dendritic cells als carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. of Immunotherapy. 18 (2): 86-94
253. 1995 Antigen Capture and Major Histocompatibility Class II Compartments Freshly Isolated and Cultured Human Blood Dendritic Cells J. Exp. Med. 182, 163-174
254. 1995 Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through in Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides1 J. of Immunology, 1995, 154: 5934-5943
255. 1995 Antigen Capture and Major Histocompatibility Class II Compartments of Freshly Isolated and Cultured Human Blood Dendritic Cells. J. Exp. Med. Volume 182, July 1995, 163-174
256. 1995 MHC Class II Compartments and the Kinetics of Antigen Presentation in Activated Mouse Spleen Dendritic Cells. The J. of Immunology, 1995, 154: 5715-5724
257. 1995 Eradication of Large Human β Cell Tumors in Nude Mice with Unconjugated CD20 Monoclonal Antibodies and Interleuking 21. Cancer Research 55, 2627-2634
258. 1995 Detailed Motifs for Peptide binding to HLA-A*0201 Derived from Large Random Sets of Peptides Using a Cellular Binding Assay. Human Immunology 43, 1-12
259. 1995 A Computer Program for Predicting Possible Cytotoxic T Lymphocyte Epitopes Based on HLA Class I Peptide-Binding Motifs Human Immunology 43, 13-18,
260. 1995 Cell-mediated autoimmunity in patients with Wegener’s granulomatosis (WG) B.E.P.B. Clin. Exp. Immunol 1995, 100: 186-193.
261. 1995 An Adenovirus Type 5 Early Region 1B-Encoded CTL Epitope-Mediated Tumor Eradication by CTL Clones Is Down-Modulated by an Activated ras Oncogene1. J. of Immunology, 1995, 154: 3396-3405
262. 1995 Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21RAS peptide presented by HLA-A*0201. Int. J. Cancer: 61, 389-396
263. 1995 Major Differences in Transporter Associated with Antigen Presentation (TAP)-Dependent Translocation of MHC Class I-Presentable Peptides and the Effect of Flanking Sequences. J. of Immunology 154: 1273-1279
264. 1995 Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. AIDS 1995, 9: 121-127
265. 1995 Treatment of low-grade non-Hodgkin’s lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother 40: 37-47
266. 1995 Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape. Biochemical Society Transactions, Volume 23
267. 1995 Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization. Immunology Letter 47: 1-8
268. 1995 Antibodies against p53 are associated with poor prognosis of colorectal cancer British J. of Cancer (1995)72, 673-641
269. 1995 Integration vectors for antibody chimerization by homologous recombinantion in hybridoma cells Eur. J. Immunol. 1995, 25, 792-797
270. 1995 Enhanced Antitumor Effects of CD20 over CD19 Monoclonal Antibodies in a Nude Mouse Xenograft Model1 Cancer Research 55, 840-846
271. 1995 CTL Specific for the Tyrosinase Autoantigen Can Be Induced from Health Donor Blood to Lyse Melanoma Cells1. The J. of Immunology, 1995, 154: 3991-3998
272. 1995 Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21RAS peptide presented by HLA-A*0201 Int. J. Cancer: 61, 389-396
273. 1994 Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. of Immunology 1994; 152: 3904-3912
274. 1994 Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer Annals of Oncology 1994; 5: 179-181
275. 1994 The relationship between class I binding affinity and immunogenecity of potential cytotoxic T cell epitopes. J. of Immunology 1994; 153: 5586-5592
276. 1994 Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Molecular Immunology 1994; 31: 1391-1401.
277. 1994 p53, a potential target for tumor-directed T cells. Immunology Letters 1994; 40: 171-178
278. 1994 Identification of an H-2 Kb –presented moloney murine leukemia virus cytotoxic T-lymphocyte epitope that displays enhanced recognition in H-2 Db mutant bm13 mice J. of Virology 1994; 68: 6038-6046
279. 1994 Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity. J. of Immunotherapy 1994; 15: 119-128
280. 1994 Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes J. of Immunology 1994; 152: 106-116
281. 1994 Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor J. of Immunotherapy 1994; 18 (2): 86-94.
282. 1994 Strategies for T-cell immunotherapy of cancer. Progress in allergy and clinical immunology Volume 3, Stockholm. Hogrefe&Huber Publishers, Seattle-Toronto-Bern-Göttingen
283. 1994 Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes. J. of Immunology 1994; 152: 106-116
284. 1994 Prospects for T cell immunotherapy of tumours by vaccination with imunodominant and subdominant peptides. Vaccines against virally induced cancers. Wiley, Chichester (Ciba Foundation Symposium 187) p97-112
285. 1993 Prospects of T cell immunotherapy for cancer by peptide vaccination. Seminars in Hematology, vol. 30, no. 3, suppl 3: 32-33,
286. 1993 Potential immunogenicity of oncogene and tumor suppressor gene products Current Opinion in Immunology 5: 709-713
287. 1993 Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction J. of Immunology 151: 767-776
288. 1993 Characterization of two human monoclonal antibodies reactive with HLA-B12 and HLA-B60, respectively, raised by in vitro secondary immunization of peripheral blood lymphocytes. Bruning. Human Immunology 36: 186-192
289. 1993 In vivo detection of fluorescent tumor-specific cytotoxic T cell clones. J. of Immunological Methods 163: 23-32
290. 1993 Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23: 2242-2249
291. 1993 In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23: 2072-2077
292. 1993 Identification of peptide sequences that potentially trigger HLA-A2.1 restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23: 1215-1219,
293. 1993 Strict peptide length is not required for the induction of cytotoxic T lymphocyte mediated antiviral protection by peptide vaccination Eur. J. Immunol. 23: 1189-1192
294. 1993 Regulatory effect of interleukin-4 (IL-4) on the expression and function of lymphocyte adhesion receptors involved in IL-2 induced cell aggregation Immunology 78: 244-251
295. 1993 Differential effect of transporter Tap 2 gene introduction into RMA-S cells on viral antigen processing. M.A. Eur. J. Immunol. 23: 3082-3088
296. 1993 A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. Br. J.. Cancer 68: 559-567
297. 1993 Reconstitution of recombinant interleukein-2 (rIL-2): a comparative study of varius rIL-2 muteins Eur. J. Cancer vol. 29A, no. 14: 1977-1979
298. 1993 A human monoclonal antibody, produced following in vitro immunization, recognizing an epitope shared by HLA-A2 subtpes and HLA-A28. Bruning. Tissue Antigens 42: 27-34
299. 1993 Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon a. Cancer Immunology Immunotherapy 36: 163-170
300. 1992 Genomic organization and chromosomal localization of the human CD27 gene. The J. of Immunology, Vol. 149, 3937-3943,
301. 1992 A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation. J. of Immunological Methods, 155 (1992) 101-111.
302. 1992 Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses Eur. J. Immunol. 1992, 22: 3013-3020
303. 1992 Processing and presentation of intact hen egg-white lysozyme by dendritic cells Eur. J. Immunol. 22: 2347-2352
304. 1992 Role of LFA-1 and VLA-4 in the adhesion of cloned normal and LFA-1 (CD11/CD18)-deficient T cells to cultured endothelial cells. Indication for a new adhesion pathway. The J. of Immunology, Vol. 148, 1093-1101, No. 4
305. 1992 Both LFA-1-positive and -deficient T cell clones require the CD2/LFA-3 interaction for specific cytolytic activation. Eur. J. Immunol. 22: 1467-1475
306. 1992 A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part 1: clinical aspects. Br. J. Cancer 65: 744-750
307. 1992 Polyclonal expansion of T-cell receptor-γδ+ T lymphocytes associated with neutropenia and thrombocytopenia. Leukemia 6, 410-418
308. 1992 Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor cell line. Eur. J. Immunol. 22: 1639-1642
309. 1992 Protection from lethal graft-versus-host disease by donor stem cell repopulation Eur. J. Immunol. 22: 575-579
310. 1992 Lessons from T cell responses to virus induced tumours for cancer eradication in general Cancer Surveys, Vol. 13, A new look at tumour immunology, 1992. pp 81-99
311. 1992 Adhesion of T and B lymphocytes to extracellular matrix and endothelial cells can be regulated through the ß subunit of VLA. J. of Cell Biology 117, 461-470
312. 1992 Tumor eradication by adoptive transfer of cytotoxic T lymphocytes Advances in cancer research 58, Academic Press, p 143-175
313. 1991 Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with an unbound synthetic peptide. Proc.Natl.Acad.Sci. USA, 88:2283-2287
314. 1991 In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes Immunology Letters, 30 229-232
315. 1991 Remission of monoclonal chronic T-cell expansion associated with severe anemia. Leukemia Research. Vol. 15, No. 12, pp. 1167-1174
316. 1991 Pretransplantation blood transfusion revisited. New Engl. J. Med. 326, 1210-1213
317. 1991 T-cell immunotherapy of cancer. Res. Immunol. 142, 425-429
318. 1991 The promise of T cell immunotherapy of cancer Advances in Haemapheresis. Kluwer Academic Publishers Developments in hematology and immunology 25.
319. 1991 Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-mhc binding. Int. J. Cancer: supplement 6, 90-94
320. 1991 Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol. 32: 364-372
321. 1991 Peptide selection by MHC class I molecules. Nature 350: 25-30
322. 1991 Cytoxic T lymphocyte therapy of cancer and tumor escape mechanisms. Cancer Biology 2, 347-354
323. 1991 Mechanisms of transplantation tolerance: do anti-idiotypic antibodies play a role? Transplantation Proceedings, vol. 23, No. 1 (February) 1991, pp 151-156
324. 1990 Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic major histocompatibility complex antigens Human Immunology 29, 220-228
325. 1990 Mutations in the major histocompatibility complex class I antigen-presenting groove affect both negative and positive selection of T cells Eur. J. Immunol. 20: 2333-2337
326. 1990 Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells. EMBO J. 9, no. 8, pp 2621-2629
327. 1990 Phenotypic and genotypic analysis of large-cell lymphomas, formerly classified as true histiocytic lymphoma: identification of an unusual group of tumors. Leukemia Research 14: 337-346
328. 1990 Persistence of allospecific helper T cells is required for maintaining autoantibody formation in lupus-like graft-versus-host disease. Clin. Exp. Immunol. 82, 527-532
329. 1990 Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies Cancer Research 50, 5767-5772
330. 1990 Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 62: 563-567
331. 1990 Efficacy of cytotoxic T lymphocytes against virus-induced tumors. Cancer Cells 2: 116-120
332. 1990 N-linked glycan modification on antigen-presenting cells restores an allospecific cytotoxic T cell response. J. Exp. Med. 171: 583-588
333. 1990 Treatment with monoclonal anti-CD3 antibody protects against lethal sendai virus infection by induction of natural killer cells. J. of Immunology 145: 2254-2259
334. 1990 Induction of transplantation tolerance by intravenous injection of allogeneic lymphocytes across an HA-2 class II mismatch. Different mechanisms operate in tolerization across an H-2 class I vs. H-2 class II disparity. Eur. J. Immunol. 20: 441-444
335. 1990 T cell differentation and function. Current Problems in Dermatology 19: 1-8,
336. 1989 Immuuntherapie, nieuw perspectief voor de bestrijding van kanker? Informatiekrant Biowetenschappen en Maatschappij, 1989 pag. 7
337. 1989 Doorbraken in de immunologie en kankertherapie. Biotechnologie is de grote stimulans Biovisie 69: 160
338. 1989 Doorbraken in de immunologie en de betekenis hiervan voor de kankertherapie Medisch Contact. Klinische Immunologie 1989 (Geneeskunde Gebiologeerd KNMG Congres 1989)
339. 1989 T cell depletion in transgenic mice carrying a mutant gene for TCR-b. Nature 341: 742-746
340. 1989 Allosuppression of B cells in vitro by graft-vs.-host reaction-derived T cells is caused by cytotoxic T lymphocytes. Eur. J. Immunol. 19: 1669-1675
341. 1989 Functional and molecular characterization of B cell line derived interleukin-1a. F.A. Leukemia 3: 585-592
342. 1989 Specific immune responses restored by alteration in carbohydrate chains of surface molecules on antigen-presenting cells. Eur. J. Immunol. 19: 537-542,
343. 1989 Alternative molecular form of human T cell-specific antigen CD27 expressed upon T cell activation. Eur. J. Immunol. 19: 357-364
344. 1989 Efficiënte therapie van adenovirus-geïnduceerde tumoren met cytotoxische T-cellen. Ned. Tijdschr. Geneesk. 133
345. 1989 Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursors. Transplantation 48: 844-847
346. 1989 Transfusion-induced skin allograft enhancement across and H-2 Class-I mismatch is caused by a clonal deletion of donor-specific cytotoxic T-lymphocyte precursors within the allograft. Transplantation Proceedings 21: 1169-1170
347. 1989 Treatment of human B-cell lymphoma with anti-CD19 monoclonal antibody and with a combination of anti-CD19 and IL-2. Mechanisms of Action and Therapeutic Applications of Biologicals in Cancer and Immune Deficiency Disorders 1989; 293-303
348. 1989 Eradication of adenovirus E1-induced tumors by E1-A-specific cytotoxic T lymphocytes. Cell 59: 603-614
349. 1989 Potentiation by Interleukin 2 of Burkitt’s lymphoma therapy with anti-Pan B (Anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Cancer Research 49: 3783-3788
350. 1989 Primary virus-induced lymphomas evade T cell immunity by failure to express viral antigens J. Exp. Med. 169: 1233-1254
351. 1989 Retrovirally induced murine B-cell tumors rarely show proviral integration in sites common in T-cell tumors. Int. J. Cancer 43: 1120-1125
352. 1989 Distinct chromosomal abnormalities in murine leukemia virus-induced T- and B-cell lymphomas Int. J. Cancer 43: 1112-1119
353. 1989 Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells. J. of Immunology 142: 4113-4117
354. 1989 Immunosurveillance of virus-induced tumors Cold Spring Harbor Symposia on Quantitative Biology Volume LIV 1989: 597-603
355. 1988 Stimulation with dendritic cells decreases or obviates the CD4+ helper cell requirement in cytotoxic T lymphocyte responses. Eur. J. Immunol. 18: 219-223
356. 1988 Anti-CD27 monoclonal antibodies identify two functionally distinct subpopulations within the CD4+ T cell subset*. Eur. J. Immunol. 18: 811-816
357. 1988 Idiotypic Immunoglobulin Secretion by Human B cell Non-Hodgkin’s Lymphomas Is Ralated to the Expression of the Interleukin-2 Receptor. Leukemia 2: 231-235
358. 1988 Production of mouse monoclonal antibodies for the analysis of idiotypes in serum of patients with chronic lymphatic leukaemia. British J. of Haematology 68: 11-16
359. 1988 Regulatory role of the CD8 antigen in both CD3 and CD2 monoclonal antibody-induced nonspecific cytotoxicity of class I- and class II-allospecific cytotoxic T cell clones Eur. J. Immunol. 18: 1973-1978,
360. 1988 Major Histocompatibility complex xlass II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas. J. of Virology 62: 3156-3166
361. 1988 Dendritic cells and antigen presentation in the regulation of cytotoxic T lymphocyte responses against viruses and transplantation antigens Cytotoxic T Cells, Ann. NY Acad. Sci. vol. 532 august 30, 1988, p 280-291.
362. 1988 Role of dendritic cells in the regulation of class I restricted cytotoxic T lymphocyte responses J. of Immunology 140: 3331-3337
363. 1988 Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells J. of Immunology 140: 3186-3193
364. 1988 Differential recognition by human cytotoxic T cell clones of human M1 fibroblasts transfected with an HlA-B7 gene (JY150) suggests the existence of two diffentent HLA-B7 alleles in the cell line JY (HLA-A2,2;B7,7;Cw-,-;DR4,w6)1. J. of Immunology 141: 417-422
365. 1987 Thymic immune response gene function in radiation chimeras reconstituted with purified hemopoietic stem cells. Eur. J. Immunol. 17: 471-475
366. 1987 Refinement and Precision in the Classification of Murine Lumphomas by Genotyping with Immunoglobulin and T cell receptor probes. Leukemia 1: 155-162
367. 1987 A T-cell receptor γ/CD3 complex found on cloned functional lymphocytes. Nature 325: 683-688
368. 1987 Anti-HLA –class II momoclonal antibodies inhibit plyclonal B cel differentiation in vitro at the accessory cell level. Eur. J. Immunol. 17: 881-886
369. 1987 Mechanism of inhibition and induction of cytolytic activity in cytotoxic T lymphocytes by CD3 monoclonal antibodies. J. of Immunology 139, 2545-2550
370. 1987 Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J. of Immunology 139: 1589-1596
371. 1986 Virology, genetics and immunology of murine lymphomagenesis Biochemica et Biophysica Acta 865: 197-231
372. 1986 Cooperation between cytotoxic and helper T lymphocytes in protection against lethal sendai virus infection. Protection by T cells in MHC-restricted and MHC-regulated; a model for MHC-Disease associated. J. Exp. Med. 164: 723-738
373. 1986 Immunobiology of the expanded T cells in T-cell leukemia and T-Gamma lymphocytosis. Leukemia Research 10: 469-474
374. 1986 Fine specific of Human HLA-B7-specific cytotoxic T-Lymphocyte Clones. I. Identification of HlA-B7 Subtypes and Histotopes of the HlA-B7 Cross-Reacting Group. G.A. van Seventer, B. Huis, C.J.M. Melief, P. Ivanyi.
375. 1986 Imbalanced MhC class II Molecule expression at surface of murine B cell lymphomas. J. Exp. Med. 163: 1213-1226
376. 1986 Differences in Oncogenicity among murine leukemia virus isolates are not corretated with the magnitude of H-2 regulated anti-viral envolope antibody responses. Leukemia Research 10: 1121-1129
377. 1986 Ecotropic and Mink Cell focus-forming Murine Leukemia Viruses Integrate in Mouse T, B, and Non-T/non-B Cell lymphoma DNA.. J. of Virology 57: 1037-1047
378. 1986 T-cell repertoire tuning by the MHC in protection against lethal virus infection and in rejection of H-Y disparate skin grafts. Regulation of immune gene expression. The humana Press, Inc., 1986, p 275-285.
379. 1986 Immunologic induction of malignant lymphoma: graft-vs-host reaction-induced B cell lymphomas contain integrations of predominantly ecotropic murine leukemia proviruses. J. of Immunology 136: 331-338
380. 1986 Antibodies to the Human T-cell lymphoma/Leukemia Virus Type I in Dutch Haemophiliacs. Vox Sang 50: 12-15
381. 1986 Transmission of Lymphotropic Retroviruses (HTLV-I and LAV/HTLV-III) by Blood Transfusion and Blood products. Vox Sang 50: 1-11
382. 1986 Lymphokines and cytokines. Cancer Chemotherapy and Biological Response Modifiers Annual 9, 1987, p 432-453, H.M. Pinedo et al. Eds
383. 1986 K-cell lymphocytosis/neutropenia syndrome: the neutropenia is not caused by autoimmunity British J. of Haematology 64: 777-787
384. 1986 MHC cancer associations the H-2 complex regulates both the susceptibility to mouse viral lymphomagenesis and the phenotype of the virus-induced lymphomas. J. of Immunogenetics 13, 69-76
385. 1986 Evidence for a regulatory role of the T8 (CD8) antigen in antigen-specific and anti-T3-(CD3)-induced lytic activity of allospecific cytotoxic T lymphocyte clones*. Eur. J. Immunol. 16: 1363-1371
386. 1986 Alternative Splicing in the Mouse H-2Kd Gene is not necessary for the classical Kd Antigen function. Immunogenetics 24: 267-274
387. 1985 Productive HTLV-III Infection of Human B cell lines. The Lancet 6: 815-816
388. 1985 Immunoglobulin Subclasses of Antibodies to Human T-Cell Leukemia/Lymphoma Virus I-Associated Antigens in Acquired Immune Deficiency Syndrome and Lympoma Virus I-Associated Antigens in Acquired Immune Deficiency Syndrome and Lymphadenopathy Syndrome. J. of Virology 53: 287-291
389. 1985 H-2 Class I Mutants Utilize Novel Restriction Specificities in the Trinitrophenyl-Specific cytotoxic T-Lymphocyte Response. Cellular Immunology 95, 420-427
390. 1985 Analysis of Helper Activity on Pokeweed Mitogen- and Interleukin 2-driven Immunoglobulin Synthesis by Neoplastic T4+ cells. J. Clin. Invest. 76: 2139-2143
391. 1985 Lymphocyte function-associated antigen 1 (LFA-1) is a marker of mature (immunocompetent) lymphoid cells. A survey of lymphoproliferatife diseases in man. Leukemia Research 9: 1099-1104
392. 1985 T-cell regulation of human B-cell activation. Immunology Today 6: 258-259
393. 1985 T Cels in Patients with Chronic Tγ Lymphocytosi: Morphology, Cytochemistry, Ultrastructure and Immunological Characteristics. Blut 51: 83-95
394. 1985 Tγ lymphocytosis is clinically non-progressive but immunologically heteropgeneous. Clin. Exp. Immunol. 61: 440-449
395. 1985 Adult T-cell lymphoma (ATLL) associated with human T-cell leukaemia virus (HTLV). Neth. J. Med. 28: 285-290
396. 1985 Immunological studies with LFA-1- and Mo1-deficient lymphocytes from a patient with recurrent bacterial infections. J. of Immunology 134: 3075-3081
397. 1985 Induction of immunoglobulin synthesis by interleuking 2 is T4+/T8- cell dependent. A role for interleuking 2 in the pokeweed mitogen-driven system*. Eur. J. Immunol. 15: 107-112
398. 1985 Abolition of specific immune response defect by immunization with dendritic cells. Nature 318: 59-62
399. 1984 Both Fc receptors and lymphocyte-function-associated antigen 1 on human Tγ lymphocytes are required for antibody-dependent cellular cytotoxicity (killer cell activity)*. Eur. J. Immunol. 14: 518-523
400. 1984 Thymus dictates major histocompatibility com,plex (MHC) specificity and Immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells J. Exp. Med. 160: 1752-1766
401. 1984 Murine leukemia Virus-Induced T-cell Lymphomagenesis: Integration of Proviruses in a Distinct Chromosomal Region. Cell. Vol. 37, 141-150
402. 1984 Further evidence against random polyclonal antibody formation in mice with lupus-like graft-vs-host disease. J. of Immunology 132: 1814-1820
403. 1984 Ecotropic and Dualtropic Mink cell focus-Inducing Murine Leukemia viruses Can Induce a Wide Spectum of H-2 Controlled Lymphoma types. Virology 138, 198-211
404. 1984 Regulatory activity of neoplastic T cells in sezary syndrome on in vitro immuynoglobulin production*. Leukemia Research, Vol. 8: 873-884
405. 1984 Serological evidence for transmission of human T cell leukemia-lymphoma virus in a dutch homosexual male after anal intercourse with an AIDS patient. Acquired Immune Deficiency Syndrome, pages 101-106, 1984, Alan R. Liss, New York.
406. 1984 Immunity against moloney sarcoma virus in H-2Db mutant bm14 mice. Unimpaired tumor immunity despite absence of a virus-specific cytotoxic T-cell response. Int. J. Cancer: 33, 265-269
407. 1984 IgG antibodies to HTLV-III associated antigens in patients with AIDS and at risk for aids in the Netherlands. AIDS Research, Volume 1, number 4, 1984. Pp. 231-236.
408. 1984 The lymphatic leukemias. Immunohaematology, 1984, Elsevier C.P. Engelfriet et al. Ed., p. 301-321.
409. 1984 Recognition of H-2Kb mutant target cells by moloney virus-specific cytotoxic T lymphocytes from bm13 (H-2Db-mutant) mice. I Involvement of discrete kb determinants. J. of Immunology 133: 24-27
410. 1984 Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation EMBO J. 3: 3215-3222
411. 1984 Functional properties of neoplastic T cells in adult T cell lymphoma/Leukemia Patients from the caribean. Blood 63: 477-481
412. 1983 Diversity in the interaction of influenza-A-specific cytotoxic T cells with H-2Kb mutant targets Immunogenetics 17: 543-549
413. 1983 Specific and regulation of Cytotoxic T-lymphocyte responses analyzed with H-2 mutants Transplantation Proceedings 15: 2086-2089
414. 1983 Immunological typing of acute lymphoblastic leukaemia. Scand. J. Haematol 30: 356-366
415. 1983 Direct demonstration that cytotoxic T lymphocytes recognize conformational determinants and not primary amino acid sequences*. J. Exp. Med. 158: 1720-1726
416. 1983 Cytotoxic T lymphocyte nonresponsiveness to the male antigen H-Y in the H-2Db mutants bm13 and bm14 complementation of the response in F1 crosses with the I-Ab mutant bm12 nonresponder and failure of B6 or Db mutant mice tolerant of each other to respond to allogeneic male cells*. J. Exp. Med. 158: 1537-1546
417. 1983 Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. Nature 305: 776-779
418. 1983 Enzyme analysis of lymphoproliferative diseases: a useful addition to cell surface phenotyping. Blood 62: 669-676
419. 1983 Naturally Occuring Leukemia Viruses in H-2 Congenic C57BL Mice. III Characterization of C-type viruses isolated from lymphomas induced by milk transmission of B-ecotropic virus. Virology 125, 47-63
420. 1983 Remodelling the H-2 map. Immunology Today 33: 57-61
421. 1983 Regulation of the cytotoxic T lymphocyte response against sendai virus analyzed with H-2 Mutants. J. of Immunology 130: 1090-1096
422. 1983 The effect of mutations in H-2Kb on target cell recognition by Kb-restricted cytotoxic T lymphocytes directed against moloney leukemia virus. Intercellular Communication in Leucocyte Function, J.W. Parker, Ed., John Wiley & Sons, p 23-26.
423. 1983 H-2 control of the cytotoxic antibody response agianst a newly defined MuLV-related cell-surface antigen:G. Int. J. Cancer: 31, 617-626
424. 1983 Nonresponsiveness to the male antigen H-Y in H-2 I-A-Mutant B6.C-H-2bmt12 is not caused by defective antigen presentation. J. of Immunology 130: 655-660
425. 1983 Mutations in H-2Kb influence the specifity of alloreactive effector cells included in the repertoire of H-2Db-Restricted cytotoxic T lymphocytes against moloney leukemia virus. Immunogenetics 17: 427-436
426. 1983 Intra-H-2 and T cell requirements for the induction of maximal positive and negative allogeneic effects in vitro*. Eur. J. Immunol 1983, 13: 191-197.
427. 1982 Effect of Nu/Nu gene on Genetically Determined Resistance to Murine Cytomegalovirus. J. Gen. Virol, , 61, 133-136.
428. 1982 Chronic Lymphocytic Leukemia. Immunologic Markers and Functional Properties of the Leukemic Cells. Cancer 50: 2826-2833,
429. 1982 Variable MLC stimulatory capacity of neoplastic B and non-B/non-T lymphocytes expressing HLA-DR antigens. Tissue antigens 20, 352-363
430. 1982 Immunological Characterization of Non-Hodgkin’s Lymphoma: Enrichment of Neoplastic Cells from Lymphoid Tissues and Blood. Cancer 49: 1605-1612
431. 1982 Evidence for a Protective Role of Interferon in Resistance to Murine Cytomegalovirus and Its control by Non-H2-Linked Genes. Infection and Immunity 37: 143-150
432. 1982 A crucial role of the H-2 D locus in the regulation of Both the D- and the K-associated cytotoxic T lymphocyte response against moloney leukemia virus, demonstrated with two Db mutants1. J. of Immunology 128: 1360-1364
433. 1982 Functional properties of T cells in patients with chronic Tγ lymphocytosis and chronic T cell neoplasia. J. of Immunology 129: 419-426
434. 1982 Characterization of two subsets of human Tγ cells. J. of Immunology 128: 1979-1985
435. 1981 Genes of the H-2 complex regulate the antibody response to murine leukemia virus. J. of Immunology 126: 2355-2360
436. 1981 Fine Specificity of Cytotoxic T Lymphocytes Directed Against H-2Ld. Immunogenetics 12: 75-88
437. 1981 Cytotoxic T cell response against lymphoblast infected with Moloney (Abelson) murine leukemia virus. Methodological aspects and H-2 requirements. Eur. J. Immunol. , 11: 251-257.
438. 1981 Cytotoxic T lymphocytes generated across an I-Ab mutant difference are directed against a molecule bearing Ia antigens Eur. J. Immunol. , 11: 258-265.
439. 1981 Three functionally distinct subsets of Tγ lymphocytes and unusual suppressor cells in patients with chronic lymphoproliferative disease. C. Melief, H. Rumke, H. v.d. Reijden, R. ten Berge, R. v.d. Griend, W. Zeijlemaker, A. Astaldi, M. van ’t Veer, A. v.d. Borne.
440. 1981 Three functionally distinct subsets of Tγ lymphocytes in patients with chronic lymphoproliferative disease. Leukemia Markers, W. Knapp. Ed., Academic press p. 351-354
441. 1980 Proliferation of Tγ cells with killer-cell activity in patients with neutropenia. New England J. of Med. 303: 882-883
442. 1980 Anti-H-2 Antibodies Induced by Syngeneic Immunization. Immunogenetics 10: 319-332
443. 1980 Unexpected Lympho-cytotoxic reactions of anti-H-2 sera on normal lymph-node cells: are they due to altered H-2 structures or anti-viral antibodies? J. of Immunogenetics 7: 91-97
444. 1980 Cryopreservation of Cells for Immunologizal Typing of Non-Hodgkin’s Lymphomas1. Cancer Research 40: 2890-2894
445. 1980 Naturally occurring leukemia viruses in H-2 congenic C57 BL mice II. Antibody response to viral envelope antigens. J. Nat. Cancer Inst. 64: 1191-1198
446. 1980 Naturally Occuring Leukemia Viruses in H-2 Congenic C57BL Mice. I. High Lymphoma Incidence Following Milk-Borne Transmission of Virus. J. Nat. Cancer Inst. 64: 1179-1189,
447. 1980 Fine specificity of alloimmune cytotoxic T lymphocytes directed against H-2K. A Study with Kb Mutants* J. Exp. Med. ; 151: 993-1013.
448. 1980 Proliferation of Tγ cells with killer-cell activity in two patients with neutropenia and recurrent infections. New England J. of Med 302: 933-937
449. 1980 H-2 control of the immune response against murine leukemia virus C.J.M. Melief, A. Vlug, H. Schoenmakers.
450. 1979 Immunodifferentiation of non-hodgkin’s lymphomas. Elsevier/North Holland Biomedical Press. Tumor Markers: Impact and Prospects E. Boelsma and Ph. Rumke, editors
451. 1979 Lymphocytotoxic antibodies produced by H-2 allo-immunisation distinguish between MuLV-positieve and –negative substrains of the same H-2 haplotype. Nature 282: 20-27
452. 1979 Granulocyte-specific Alloantigen Loss in Chronic Granulocytic Leukaemia. British J. of Haematology, , 43, 589-594.
453. 1979 Individual Mice Recognize the Complex Nature of H-2 Antigens: Unexpected Reactions (Anti-Kk) in Anti-BALB/c-H-2d Sera Produced in the BALB/c-H-2db Mutant. Transplantation Proceedings, Vol XI, No. 1 (March)
454. 1979 Een lymfoproliferatieve aandoening van T-cel-oorsprong met de verschijnselen van chronische lymfatische leukemie. Ned. T. Geneesk. 123, nr. 51
455. 1979 Cooperation between subclasses of T lymphocytes in the in vitro generation of cytotoxicity against a mutant H-2K difference. An analysis with anti-Lyt antisera Eur. J. Immunol. . 9:7-12
456. 1978 Lymphomagenesis and autoimmunization caused by reactions of T-lymphocytes to incompatible structures of the major histocompatibility complex: a concept of pathogenesis. Recent Results in Cancer Research ; 64: 292-315.
457. 1978 Genetic differences unrelated to H-2 in H-2-congenic mice Immunogenetics ; 7: 359-365.
458. 1978 Surface markers and functional properties of non-Hodgkin’s lymphoma cells in relation to histology. Cancer ; 42: 1804-1817.
459. 1977 Immunological characterization of the malignant cells in non-hodgkin lymphomas. Advances in Comparative Leukemia Research ; 387-390.
460. 1977 Effector cell specificity in histoincompatibility without serologically detectable differences. 8th Round Table symposium on applied immunology. Eur. Surg. Res. ; 9: 280-301.
461. 1977 CML typing of serologically identical H-2 mutants. Distinction of 19 specificities on the cells of four mouse strains carrying z1 locus mutations and the strain of origin. Immunogenetics ; 5: 43-56.
462. 1977 Ecotropic type C RNA virus expression and its consequences in congenic resistant C57BL mice. Advances in Comparative Leukemia Research ; 78-83.
463. 1976 Immunity to C-type RNA viruses: antibody formation after natural or deliberate infection. J. Immunology ; 116 (3): 657-660.
464. 1975 Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur. J. Immunol, 29: 1292-1303,
465. 1975 Splenocyte plaque assay for the detection of murine leukemia virus (38946). Proc. Society for Exp. Biology and Medicine ; 149: 1015-1018.
466. 1975 Ecotropic leukemia viruses in congenic C57BL mice: natural dissemination by Milk-Borne infection. J. National Cancer Institute ; 55: 691-698.
467. 1974 Immunologic activation of murine leukemia viruses Cancer ; 34 (4): 1481-1487.
468. 1974 Recognation of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 9: 1344-1348
469. 1973 Studies on tumor immunity in acute lymphatic leukemia and on transformation kinetics in chronic lymphocytic leukemia. Proceedings of the seventh leucocyte culture conference 1973, Academic Press, Inc., New York and London.
470. 1973 Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinitiy and immune responsiveness to peptides. J. of Immunotherapy 14: 121-126
471. 1973 Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur. J. Immunol. 21: 2963-2970
472. 1973 Lymphoid dendritic cells: their life history and roles in immune responses Res. Immunol. 140: 877-926
473. 1973 Mechanism of skin allograft enhancement across an H-2 class I mutant difference. Evidence for involvement of veto cells* Eur. J. Immunol. 18: 2105-2108
474. 1973 Recognition of H-2 kb mutant target cells by maloney virus-specific cytotoxic T lymphocytes from bm13 (H-2 Db mutant) mice. II Relationship of Kbm3 and KbmII in restriction specificities and allodeterminants. J. Immunology 133: 28-32
475. 1973 Chronic lymphocytic leukaemia in 5 siblings. Scand. J. Haemat. ; 11: 97-105.
476. 1973 Some immunological properties of lymphoid cells from patients with acute lymphatic leukaemia (ALL). Clin. Exp. Immunol. ; 15: 131-143
477. 1973 Lymphocyte transformation in vitro Exp. Cell Research ; 79: 257-262.
478. 1973 Failure to demonstrate immunity to leukemia associated antigens by lymphocyte transformation in vitro. Int. J. Cancer ; 11: 11-18.
479. 1972 Position of a locus determining mixed lymphocyte reaction (MLR), distinct from the known HL-A loci, and its relation to cell – mediated lympholysis (CML). Histocompatibility Testing ; S. Karger, p 501-508.
480. 1972 T-chronic lymphocytic leukaemia presenting as primary hypogammaglobulinaemia-evidence of a proliferation of T-suppressor cells Clin. Exp. Immunol. 47: 670-676
481. 1968 Demonstration of leucocyte isoantigens on skin cells by means of immune adherence. Vox Sang. ; 15: 187-193.
482. 1968 Workshop on H-2 Antigens Immunogenetics 9: 305-326
483. 1967 Immune adherence of leucocytes and fibroblasts derived from skin, sensitized by cytotoxic leucocyte iso-antibodies and complement, to the surface of indicator cells. Vox Sang. ; 12: 374-389.
484. 1967 Dermal histocompatibility and in vitro lymphocyte reactions of three new H-2 mutants Immunogenetics ; 2: 337-348.

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.